Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
- PMID: 38446126
- PMCID: PMC11032711
- DOI: 10.1093/eurheartj/ehae086
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
Abstract
Background and aims: What is the relationship between blood tests for iron deficiency, including anaemia, and the response to intravenous iron in patients with heart failure?
Methods: In the IRONMAN trial, 1137 patients with heart failure, ejection fraction ≤ 45%, and either serum ferritin < 100 µg/L or transferrin saturation (TSAT) < 20% were randomized to intravenous ferric derisomaltose (FDI) or usual care. Relationships were investigated between baseline anaemia severity, ferritin and TSAT, to changes in haemoglobin from baseline to 4 months, Minnesota Living with Heart Failure (MLwHF) score and 6-minute walk distance achieved at 4 months, and clinical events, including heart failure hospitalization (recurrent) or cardiovascular death.
Results: The rise in haemoglobin after administering FDI, adjusted for usual care, was greater for lower baseline TSAT (Pinteraction < .0001) and ferritin (Pinteraction = .028) and more severe anaemia (Pinteraction = .014). MLwHF scores at 4 months were somewhat lower (better) with FDI for more anaemic patients (overall Pinteraction = .14; physical Pinteraction = .085; emotional Pinteraction = .043) but were not related to baseline TSAT or ferritin. Blood tests did not predict difference in achieved walking distance for those randomized to FDI compared to control. The absence of anaemia or a TSAT ≥ 20% was associated with lower event rates and little evidence of benefit from FDI. More severe anaemia or TSAT < 20%, especially when ferritin was ≥100 µg/L, was associated with higher event rates and greater absolute reductions in events with FDI, albeit not statistically significant.
Conclusions: This hypothesis-generating analysis suggests that anaemia or TSAT < 20% with ferritin > 100 µg/L might identify patients with heart failure who obtain greater benefit from intravenous iron. This interpretation requires confirmation.
Keywords: Anaemia; Ferric derisomaltose; Ferritin; Heart failure; Iron deficiency; Morbidity; Mortality; Quality of life; Randomized clinical trial; Transferrin saturation.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Figures
Similar articles
-
The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.J Card Fail. 2024 May;30(5):682-690. doi: 10.1016/j.cardfail.2023.10.006. Epub 2023 Nov 4. J Card Fail. 2024. PMID: 37926238 Free PMC article. Clinical Trial.
-
Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure.Eur J Heart Fail. 2024 Jun;26(6):1298-1312. doi: 10.1002/ejhf.3237. Epub 2024 May 10. Eur J Heart Fail. 2024. PMID: 38727791 Review.
-
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Clinical Trial.
-
A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.BMC Nephrol. 2021 Mar 30;22(1):115. doi: 10.1186/s12882-021-02308-y. BMC Nephrol. 2021. PMID: 33784968 Free PMC article. Clinical Trial.
-
Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.Drugs. 2009;69(6):739-56. doi: 10.2165/00003495-200969060-00007. Drugs. 2009. PMID: 19405553 Review.
References
-
- World Health Organization . WHO Guideline on Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations. Geneva: WHO; 2020. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical